Cancer drug repotrectinib tested for drug interactions in healthy volunteers
NCT ID NCT07223671
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study looked at how the cancer drug repotrectinib changes the levels of other medications in the body. Thirty healthy adults took repotrectinib along with several common drugs (metformin, digoxin, rosuvastatin, bupropion, flurbiprofen, and omeprazole). The goal was to see if repotrectinib affects how these drugs are processed, which helps doctors prescribe them safely together.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Repotrectinib
What this could lead to
If successful, this study could help doctors understand how repotrectinib interacts with other medications, leading to safer dosing guidelines.
What could go wrong
This is an early-stage study in healthy volunteers, not patients. Results may not predict real-world interactions in people with cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Daytona Beach, Florida, 32117-5116, United States